Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10738938 | 0.88 | ALDH1A1 (0.48) | CA12CA1CA2CA9GAA | |
| SCHEMBL10740700 | 0.87 | LMNA (0.48) | CA12CA1CA2CA9GAA | |
| SCHEMBL10743398 | 0.84 | DGKA (0.50) | GAAALDH1A1LMNAMAPTCES2 | |
| SCHEMBL10042520 | 0.82 | GAA (0.50) | CA12CA1CA2CA9GAA | |
| SCHEMBL10050087 | 0.81 | LMNA (0.44) | CA12CA1CA2CA9GAA | |
| SCHEMBL2840377 | 0.81 | CA12 (0.60) | CA12CA1CA2CA9GAA | |
| SCHEMBL14819938 | 0.79 | LMNA (0.42) | ALDH1A1LMNAHPGDCES2CES1 | |
| SCHEMBL4690633 | 0.77 | GAA (0.50) | CA12CA1CA2CA9GAA | |
| SCHEMBL14088914 | 0.77 | GAA (0.50) | CA12CA1CA2CA9GAA | |
| SCHEMBL196815 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729030-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | AFFYMAX, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120165275-A1 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules | AFFYMAX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165275-A1 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules | DNPEP, NGLY1, LNPEP | CA12 1276/4885CA1 1155/4885CA2 4362/4885 |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CA12 3007/4885CA1 4618/4885CA2 1044/4885 |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | CA12 4226/4885CA1 4836/4885CA2 4587/4885 |
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | EPOR, MPL, PROKR1 | CA12 3745/4885CA1 4748/4885CA2 3890/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CA12 2887/4885CA1 4324/4885CA2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.